Hong Kong Electronic Equipment and Components Stock News

In recent comments, Hong Kong Exchanges and Clearing (HKEX) chief executive Bonnie Chan Yiting outlined plans to expand into digital currencies, tokenisation, and related data and analytics capabilities to support its core exchange business and round-the-clock trading demand. This push toward always-on digital asset infrastructure suggests HKEX is positioning itself to compete more directly with global peers that are extending trading hours and broadening product coverage. Next, we’ll...

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) just locked in a wide ranging oncology partnership with Crescent Biopharma, featuring exclusive regional rights along with substantial upfront and milestone payments that could significantly influence its long term growth profile. See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical. The Crescent tie up lands after a powerful run, with a year to date share price return of 142.75 percent and a 1 year total shareholder return of...

XtalPi Holdings (SEHK:2228) just signed a two year memorandum of understanding with Mirxes Holding, aiming to fuse Mirxes genomics database with XtalPi's AI plus robotics platform for earlier gastrointestinal cancer detection and intervention. See our latest analysis for XtalPi Holdings. The MOU lands at an interesting moment, with XtalPi’s share price at HK$9.26 after a weak 1 month share price return but still a strong year to date share price return and solid 1 year total shareholder...

AIA Group has recently continued its push into high-growth Asian insurance markets, including new partnership arrangements in mainland China that aim to deepen product distribution and customer reach across the region. This expansion underscores how access to mainland Chinese channels could become a major long-term driver of premium growth and competitive positioning for AIA. We’ll now examine how AIA’s mainland China partnerships may reshape its investment narrative and the outlook for...

BOC Aviation (SEHK:2588) just struck a fresh deal to buy two Airbus A350-1000s and lease them back to Philippine Airlines, a classic sale and leaseback that quietly extends its long term revenue runway. See our latest analysis for BOC Aviation. The market seems to be rewarding this steady pipeline of long term leases, with the share price at HK$74.0 and a robust year to date share price return of 26.71 percent, while the 5 year total shareholder return of 43.10 percent points to durable, if...

Guotai Junan International Holdings (SEHK:1788) has been on a rollercoaster lately, with the share price sliding 4 % today and down roughly 12 % over the past month despite a strong year to date. See our latest analysis for Guotai Junan International Holdings. That drop to HK$2.57 gives back some of the huge year to date share price return, but with the 1 year total shareholder return still firmly positive, recent momentum looks more like a breather than a reversal in sentiment. If Guotai...

Emperor International Holdings (SEHK:163) has posted another tough set of H1 2026 numbers, with total revenue of about HK$1.0 billion and a basic EPS loss of roughly HK$0.25, underscoring that the business is still running in the red. Looking back, revenue has hovered in the HK$0.6 billion range in H1 2025 and H2 2024 while EPS stayed negative between HK$0.25 and HK$0.36, and over the last 12 months the company has remained unprofitable as losses have been compounding at an 18.1% annualised...

China Medical System Holdings (SEHK:867) just cleared a meaningful hurdle, with regulators accepting its New Drug Application for Y-3 for Injection after a successful Phase III trial in acute ischemic stroke patients. See our latest analysis for China Medical System Holdings. Despite a softer 30 day share price return and some recent consolidation, China Medical System Holdings still sits at HK$13.40, with strong upward share price return year to date and a robust multi year total shareholder...

Akeso has recently reported a series of oncology milestones, including FDA approval to start a global Phase III trial of cadonilimab in advanced HER2‑negative gastric cancer and new Phase II/III data on ivonescimab in triple‑negative breast cancer and squamous non‑small cell lung cancer. Together, these updates underscore Akeso’s push to position its bispecific antibodies as potential new standards of care across multiple solid tumors, supported by both efficacy and quality‑of‑life...

In December 2025, RemeGen Co., Ltd was added to the Shanghai Stock Exchange Health Care Sector Index, marking its inclusion among China’s listed healthcare names tracked by this benchmark. This index inclusion can increase RemeGen’s visibility to institutional investors that track or reference sector indices, potentially influencing how the company is positioned in healthcare-focused portfolios. With this new index inclusion as a backdrop, we’ll examine how RemeGen’s expanding profile within...

Key Insights Lingbao Gold Group's significant retail investors ownership suggests that the key decisions are influenced...

Lenovo Group (SEHK:992) just rolled out a sweeping lineup of AI ready storage, virtualization, and data management offerings, a strategic push that could gradually reshape how investors view its infrastructure and services growth story. See our latest analysis for Lenovo Group. Against that backdrop, Lenovo’s HK$9.66 share price reflects a mixed year, with recent share price returns under pressure but a solid 1 year total shareholder return of about 9.8 percent and strong three year...

Earlier in December, Giant Biogene Holding announced a share repurchase plan, following recent analyst coverage from Citic Securities, Citi and UBS. The buyback move is being read as a signal of management confidence and a direct attempt to enhance shareholder value. With the share repurchase plan now in place, we’ll explore how this capital allocation decision shapes Giant Biogene’s broader investment narrative. AI is about to change healthcare. These 30 stocks are working on everything...

We can readily understand why investors are attracted to unprofitable companies. For example, Tai Kam Holdings...

Key Insights Hysan Development's significant private companies ownership suggests that the key decisions are influenced...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...

It's not a stretch to say that Luk Fook Holdings (International) Limited's ( HKG:590 ) price-to-earnings (or "P/E...

As global markets react to interest rate adjustments and economic uncertainties, investors are increasingly looking toward alternative investment opportunities. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever. Typically referring to smaller or relatively new companies, these stocks can provide a mix of affordability and growth potential when paired with strong financials.

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

China Resources Beer (Holdings) (SEHK:291) just picked up top honors in both Corporate Governance and ESG Excellence Awards, a signal that its sustainability and oversight practices are increasingly aligned with long term, risk aware investors. See our latest analysis for China Resources Beer (Holdings). At around HK$27.0, the shares have delivered an 11.34% year to date share price return. However, the 3 year total shareholder return of minus 44.69% shows the longer term momentum has been...

ASMPT Limited ( HKG:522 ), is not the largest company out there, but it received a lot of attention from a substantial...

Sundy Service Group Co. Ltd's ( HKG:9608 ) price-to-earnings (or "P/E") ratio of 30.6x might make it look like a strong...

DT Capital Limited's (HKG:356) stock price has dropped 13% in the previous week, but insiders who sold HK$2.8m in stock...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...